PMID- 37382018
OWN - NLM
STAT- MEDLINE
DCOM- 20230630
LR  - 20230630
IS  - 1001-5302 (Print)
IS  - 1001-5302 (Linking)
VI  - 48
IP  - 12
DP  - 2023 Jun
TI  - [Mechanism of Xuebijing Injection in treatment of sepsis-associated ARDS based on 
      network pharmacology and in vitro experiment].
PG  - 3345-3359
LID - 10.19540/j.cnki.cjcmm.20230202.703 [doi]
AB  - The aim of this study was to investigate the effect and molecular mechanism of 
      Xuebijing Injection in the treatment of sepsis-associated acute respiratory 
      distress syndrome(ARDS) based on network pharmacology and in vitro experiment. 
      The active components of Xuebijing Injection were screened and the targets were 
      predicted by the Traditional Chinese Medicine Systems Pharmacology Database and 
      Analysis Platform(TCMSP). The targets of sepsis-associated ARDS were searched 
      against GeneCards, DisGeNet, OMIM, and TTD. Weishengxin platform was used to map 
      the targets of the main active components in Xuebijing Injection and the targets 
      of sepsis-associated ARDS, and Venn diagram was established to identify the 
      common targets. Cytoscape 3.9.1 was used to build the "drug-active 
      components-common targets-disease" network. The common targets were imported 
      into STRING for the building of the protein-protein interaction(PPI) network, 
      which was then imported into Cytoscape 3.9.1 for visualization. DAVID 6.8 was 
      used for Gene Ontology(GO) and Kyoto Encyclopedia of Genes and Genomes(KEGG) 
      enrichment of the common targets, and then Weishe-ngxin platform was used for 
      visualization of the enrichment results. The top 20 KEGG signaling pathways were 
      selected and imported into Cytoscape 3.9.1 to establish the KEGG network. 
      Finally, molecular docking and in vitro cell experiment were performed to verify 
      the prediction results. A total of 115 active components and 217 targets of 
      Xuebijing Injection and 360 targets of sepsis-associated ARDS were obtained, 
      among which 63 common targets were shared by Xuebijing Injection and the disease. 
      The core targets included interleukin-1 beta(IL-1beta), IL-6, albumin(ALB), 
      serine/threonine-protein kinase(AKT1), and vascular endothelial growth factor 
      A(VEGFA). A total of 453 GO terms were annotated, including 361 terms of 
      biological processes(BP), 33 terms of cellular components(CC), and 59 terms of 
      molecular functions(MF). The terms mainly involved cellular response to 
      lipopolysaccharide, negative regulation of apoptotic process, 
      lipopolysaccharide-mediated signaling pathway, positive regulation of 
      transcription from RNA polyme-rase Ⅱ promoter, response to hypoxia, and 
      inflammatory response. The KEGG enrichment revealed 85 pathways. After diseases 
      and generalized pathways were eliminated, hypoxia-inducible factor-1(HIF-1), 
      tumor necrosis factor(TNF), nuclear factor-kappa B(NF-kappaB), Toll-like receptor, 
      and NOD-like receptor signaling pathways were screened out. Molecular docking 
      showed that the main active components of Xuebijing Injection had good binding 
      activity with the core targets. The in vitro experiment confirmed that Xuebijing 
      Injection suppressed the HIF-1, TNF, NF-kappaB, Toll-like receptor, and NOD-like 
      receptor signaling pathways, inhibited cell apoptosis and reactive oxygen species 
      generation, and down-regulated the expression of TNF-alpha, IL-1beta, and IL-6 in cells. 
      In conclusion, Xuebijing Injection can regulate apoptosis and response to 
      inflammation and oxidative stress by acting on HIF-1, TNF, NF-kappaB, Toll-like 
      receptor, and NOD-like receptor signaling pathways to treat sepsis-associated 
      ARDS.
FAU - Ding, Wei-Chao
AU  - Ding WC
AD  - Nanjing University of Chinese Medicine Nanjing 210023, China Department of 
      Emergency Medicine, Jinling Hospital(General Hospital of Eastern Theater 
      Command), Medical School of Nanjing University Nanjing 210002, China Department 
      of Emergency Medicine, the Affiliated Hospital of Xuzhou Medical University 
      Xuzhou 221002, China.
FAU - Chen, Juan
AU  - Chen J
AD  - Nanjing University of Chinese Medicine Nanjing 210023, China Department of 
      Emergency Medicine, Jinling Hospital(General Hospital of Eastern Theater 
      Command), Medical School of Nanjing University Nanjing 210002, China.
FAU - Liao, Hao-Yu
AU  - Liao HY
AD  - Department of Emergency Medicine, Jinling Hospital(General Hospital of Eastern 
      Theater Command), Medical School of Nanjing University Nanjing 210002, China.
FAU - Feng, Jing
AU  - Feng J
AD  - Department of Emergency Medicine, Jinling Hospital(General Hospital of Eastern 
      Theater Command), Medical School of Nanjing University Nanjing 210002, China.
FAU - Wang, Jing
AU  - Wang J
AD  - Department of Emergency Medicine, Jinling Hospital(General Hospital of Eastern 
      Theater Command), Medical School of Nanjing University Nanjing 210002, China.
FAU - Zhang, Yu-Hao
AU  - Zhang YH
AD  - Department of Emergency Medicine, Jinling Hospital(General Hospital of Eastern 
      Theater Command), Medical School of Nanjing University Nanjing 210002, China.
FAU - Ji, Xiao-Hang
AU  - Ji XH
AD  - Department of Emergency Medicine, Jinling Hospital(General Hospital of Eastern 
      Theater Command), Medical School of Nanjing University Nanjing 210002, China.
FAU - Chen, Qian
AU  - Chen Q
AD  - Department of Emergency Medicine, Jinling Hospital(General Hospital of Eastern 
      Theater Command), Medical School of Nanjing University Nanjing 210002, China.
FAU - Wu, Xin-Yao
AU  - Wu XY
AD  - Nanjing University of Chinese Medicine Nanjing 210023, China Department of 
      Emergency Medicine, Jinling Hospital(General Hospital of Eastern Theater 
      Command), Medical School of Nanjing University Nanjing 210002, China.
FAU - Sun, Zhao-Rui
AU  - Sun ZR
AD  - Nanjing University of Chinese Medicine Nanjing 210023, China Department of 
      Emergency Medicine, Jinling Hospital(General Hospital of Eastern Theater 
      Command), Medical School of Nanjing University Nanjing 210002, China.
FAU - Nie, Shi-Nan
AU  - Nie SN
AD  - Nanjing University of Chinese Medicine Nanjing 210023, China Department of 
      Emergency Medicine, Jinling Hospital(General Hospital of Eastern Theater 
      Command), Medical School of Nanjing University Nanjing 210002, China.
LA  - chi
PT  - English Abstract
PT  - Journal Article
PL  - China
TA  - Zhongguo Zhong Yao Za Zhi
JT  - Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese 
      materia medica
JID - 8913656
RN  - 0 (Xuebijing)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 0 (NF-kappa B)
RN  - 0 (Interleukin-6)
RN  - 0 (Lipopolysaccharides)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (NLR Proteins)
SB  - IM
MH  - Humans
MH  - Network Pharmacology
MH  - Vascular Endothelial Growth Factor A
MH  - NF-kappa B
MH  - Interleukin-6
MH  - Lipopolysaccharides
MH  - Molecular Docking Simulation
MH  - *Respiratory Distress Syndrome
MH  - Tumor Necrosis Factor-alpha
MH  - *Sepsis/complications/drug therapy/genetics
MH  - NLR Proteins
OTO - NOTNLM
OT  - Xuebijing Injection
OT  - acute respiratory distress syndrome(ARDS)
OT  - in vitro experiment
OT  - network pharmacology
OT  - sepsis
EDAT- 2023/06/29 06:43
MHDA- 2023/06/30 06:42
CRDT- 2023/06/29 05:34
PHST- 2023/06/30 06:42 [medline]
PHST- 2023/06/29 06:43 [pubmed]
PHST- 2023/06/29 05:34 [entrez]
AID - 10.19540/j.cnki.cjcmm.20230202.703 [doi]
PST - ppublish
SO  - Zhongguo Zhong Yao Za Zhi. 2023 Jun;48(12):3345-3359. doi: 
      10.19540/j.cnki.cjcmm.20230202.703.